Carbamoyl Phosphate Synthetase I Deficiency
A rare inherited urea cycle disorder that impairs the body's ability to clear ammonia, requiring rapid recognition and specialized metabolic management to prevent neurological injury.
- Urea Cycle Disorder
- Autosomal Recessive (CPS1 Gene)
- Requires Urgent Ammonia Management
- Estimated Incidence
- Roughly 1 in 300,000–1,300,000 births
- Inheritance Pattern
- Autosomal Recessive
- Gene Involved
- CPS1
- Management Anchor
- Protein Restriction & Ammonia Scavengers
Condition Overview
Carbamoyl phosphate synthetase I (CPS1) deficiency is a rare inherited disorder of the urea cycle, the metabolic pathway responsible for converting toxic ammonia into urea for excretion. CPS1 catalyzes the first and rate-limiting step of this cycle in the liver.
When CPS1 activity is severely reduced, ammonia accumulates in the blood, a condition known as hyperammonemia. In the classic neonatal-onset form, this typically occurs within the first days of life and constitutes a medical emergency. Late-onset or partial forms may present later in childhood or adulthood, often triggered by illness, high protein intake, or metabolic stress.
Because hyperammonemia can rapidly damage the developing brain, early recognition and urgent treatment are essential, alongside long-term dietary and pharmacologic management.
Types and Subtypes
CPS1 deficiency severity correlates with residual enzyme activity and age at presentation.
Symptoms and Signs
Symptoms reflect the effects of elevated ammonia on the brain and vary by age of onset.
Causes and Risk Factors
CPS1 deficiency results from biallelic pathogenic variants in the CPS1 gene, which encodes the enzyme catalyzing the first step of the urea cycle.
Diagnosis and Investigations
Diagnosis relies on recognizing hyperammonemia with a urea cycle-pattern of metabolic findings, followed by confirmatory enzyme and genetic testing.
Disease Classification and Risk Stratification
CPS1 deficiency is not staged like cancer; instead, risk is stratified by age of onset and residual enzyme activity, which guide treatment intensity.
Standard Treatment Options
Treatment combines emergency ammonia reduction during crises with long-term dietary and pharmacologic management.
Advanced and Emerging Approaches
For patients with recurrent severe hyperammonemia despite medical management, advanced options may be considered.
Transplantation
Liver Transplantation
Considered in selected severe cases with recurrent life-threatening hyperammonemia refractory to medical therapy; provides functional urea cycle capacity.
Gene Therapy
Investigational Gene-Based Approaches
Early-stage research is exploring gene therapy and mRNA-based approaches for urea cycle disorders, including CPS1 deficiency.
Biomarkers and Laboratory Monitoring
Laboratory monitoring guides treatment adjustments and crisis recognition rather than prognostic staging.
When a Second Opinion May Be Important
Given the complexity and rarity of CPS1 deficiency, expert input is valuable at several decision points.
Clinical Trials and Research
Outlook and Key Outcome Factors
Outlook in CPS1 deficiency depends heavily on how quickly hyperammonemia is recognized and treated, particularly in the neonatal period.
Supportive Care and Living with CPS1 Deficiency
Day-to-day management extends well beyond medication, requiring coordinated dietary, educational, and emotional support.
How CancerFax Helps You Explore Treatment Options
CancerFax can help families coordinate medical report review, connect with metabolic and transplant specialists for second opinions, and identify experienced centers for ongoing management of CPS1 deficiency.
Get a free case reviewFrequently Asked Questions
It is a rare inherited urea cycle disorder in which the body cannot efficiently clear ammonia, leading to its buildup in the blood.
It is caused by inherited pathogenic variants in the CPS1 gene, passed down from two carrier parents in an autosomal recessive pattern.
Diagnosis is based on elevated plasma ammonia with a characteristic amino acid pattern, confirmed by genetic testing.
Yes, through a combination of dietary protein management, ammonia-scavenging medications, and, in select cases, liver transplantation.
Ammonia rises rapidly and can cause lethargy, vomiting, seizures, or coma; it requires emergency medical treatment.
Yes, partial or late-onset forms can present later in life, sometimes triggered by illness, fasting, or pregnancy.
No, transplantation is reserved for severe, recurrent cases that do not respond adequately to medical and dietary management.
Parents of an affected child are carriers, with an approximate 25% recurrence risk in future pregnancies; genetic counseling is recommended.
No, it is a urea cycle metabolic disorder and is not associated with increased cancer risk.
Yes. CancerFax can help coordinate medical report review, facilitate second opinions with metabolic and transplant specialists, and assist with matching families to experienced centers for ongoing care.
Get Expert Guidance for CPS1 Deficiency
CancerFax can help connect you with metabolic specialists, support second opinions, and guide you through ongoing management decisions.